|Mr. Michael W. Aguiar||Chief Exec. Officer, Pres and Director||1.44M||N/A||51|
|Mr. Eric d'Esparbes||Chief Financial Officer and Sr. VP||686.28k||N/A||49|
|Dr. Theodore J. Witek Jr., MBA, Ph.D.||Chief Scientific Officer and Sr. VP||696.7k||N/A||59|
|Mr. Michael Eric Faerm||Chief Bus. Officer and Sr. VP||869.01k||N/A||50|
|Mr. Jeffrey A. Hagenah Ph.D.||Chief Patent Counsel and VP||N/A||N/A||N/A|
Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components. It has LABA collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.
Innoviva, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 4. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 3; Compensation: 8.